Survival benefit after neoadjuvant or adjuvant radiotherapy for stage II–III gastroesophageal junction adenocarcinoma: A large population-based cohort study

OBJECTIVE: The standard treatment for stage II–III gastroesophageal junction adenocarcinoma (GEJA) remains controversial, and the role of radiotherapy (RT) in stage II–III GEJA is unclear. Herein, we aimed to evaluate the prognosis of different RT sequences and identify potential candidates to under...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuo, Zhichao, Peng, Yafeng, Zeng, Ying, Lin, Shanyue, Zeng, Weihua, Zhou, Xiao, Zhou, Yinjun, Li, Bo, Ma, Jie, Long, Mingju, Cao, Shenghui, Liu, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630344/
https://www.ncbi.nlm.nih.gov/pubmed/36338703
http://dx.doi.org/10.3389/fonc.2022.998101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630344/
https://www.ncbi.nlm.nih.gov/pubmed/36338703
http://dx.doi.org/10.3389/fonc.2022.998101

Ejemplares similares